Argenx has entered a definitive agreement to acquire Forte Biosciences for $2.2 billion in cash, primarily to gain FB102, a promising anti-CD122 antibody with clinical proof-of-concept in vitiligo and celiac disease. This acquisition significantly expands Argenx's immunology pipeline and strategic focus on autoimmune diseases, positioning it for potential long-term growth in a competitive market.
Argenx is acquiring Forte Biosciences for $2.2 billion, paying $77 per share in cash. The primary driver for this acquisition is Forte's lead asset, FB102, an anti-CD122 antibody that has shown clinical proof-of-concept in treating vitiligo and celiac disease. This move is highly significant for Argenx as it directly aligns with their 'Vision 2030' strategy to be a leading immunology innovator, adding a 'pipeline-in-a-product' opportunity that complements their existing portfolio. For Forte Biosciences shareholders, this represents a substantial premium and a clear exit strategy. In the short term, FBRX shares surged close to the acquisition price, while ARGX saw a slight dip, likely due to the acquisition cost. Long-term, Argenx gains a valuable asset with potential for multiple indications, offering a key opportunity for growth in the autoimmune disease market, though integration and successful clinical development of FB102 remain crucial risks.